Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
Biopharma takeovers dry up
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
23andme joins health tech’s Spacmania
But more traditional device makers seem uninterested in this means of stock market listing.
Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
